BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 31791288)

  • 1. Efficacy and safety of sodium zirconium cyclosilicate in patients with baseline serum potassium level ≥ 5.5 mmol/L: pooled analysis from two phase 3 trials.
    Amin AN; Menoyo J; Singh B; Kim CS
    BMC Nephrol; 2019 Dec; 20(1):440. PubMed ID: 31791288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZE.
    Roger SD; Spinowitz BS; Lerma EV; Singh B; Packham DK; Al-Shurbaji A; Kosiborod M
    Am J Nephrol; 2019; 50(6):473-480. PubMed ID: 31658466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study.
    Spinowitz BS; Fishbane S; Pergola PE; Roger SD; Lerma EV; Butler J; von Haehling S; Adler SH; Zhao J; Singh B; Lavin PT; McCullough PA; Kosiborod M; Packham DK;
    Clin J Am Soc Nephrol; 2019 Jun; 14(6):798-809. PubMed ID: 31110051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.
    Kosiborod M; Rasmussen HS; Lavin P; Qunibi WY; Spinowitz B; Packham D; Roger SD; Yang A; Lerma E; Singh B
    JAMA; 2014 Dec; 312(21):2223-33. PubMed ID: 25402495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correction of serum potassium with sodium zirconium cyclosilicate in Japanese patients with hyperkalemia: a randomized, dose-response, phase 2/3 study.
    Kashihara N; Nishio T; Osonoi T; Saka Y; Imasawa T; Ohtake T; Mizuno H; Shibagaki Y; Kim H; Yajima T; Sarai N
    Clin Exp Nephrol; 2020 Dec; 24(12):1144-1153. PubMed ID: 32779057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia.
    Fishbane S; Ford M; Fukagawa M; McCafferty K; Rastogi A; Spinowitz B; Staroselskiy K; Vishnevskiy K; Lisovskaja V; Al-Shurbaji A; Guzman N; Bhandari S
    J Am Soc Nephrol; 2019 Sep; 30(9):1723-1733. PubMed ID: 31201218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium zirconium cyclosilicate in hyperkalemia.
    Packham DK; Rasmussen HS; Lavin PT; El-Shahawy MA; Roger SD; Block G; Qunibi W; Pergola P; Singh B
    N Engl J Med; 2015 Jan; 372(3):222-31. PubMed ID: 25415807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects and Safety of a Novel Oral Potassium-Lowering Drug-Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia: a Systematic Review and Meta-Analysis.
    Zhang Y; Xu R; Wang F; Liu Y; Xu J; Zhao N; Cheng F; Long L; Jia J; Lin S
    Cardiovasc Drugs Ther; 2021 Oct; 35(5):1057-1066. PubMed ID: 33459923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergency Potassium Normalization Treatment Including Sodium Zirconium Cyclosilicate: A Phase II, Randomized, Double-blind, Placebo-controlled Study (ENERGIZE).
    Peacock WF; Rafique Z; Vishnevskiy K; Michelson E; Vishneva E; Zvereva T; Nahra R; Li D; Miller J
    Acad Emerg Med; 2020 Jun; 27(6):475-486. PubMed ID: 32149451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potassium responses to sodium zirconium cyclosilicate in hyperkalemic hemodialysis patients: post-hoc analysis of DIALIZE.
    Fishbane S; Ford M; Fukagawa M; McCafferty K; Rastogi A; Spinowitz B; Staroselskiy K; Vishnevskiy K; Lisovskaja V; Al-Shurbaji A; Guzman N; Bhandari S
    BMC Nephrol; 2022 Feb; 23(1):59. PubMed ID: 35135481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial.
    Anker SD; Kosiborod M; Zannad F; Piña IL; McCullough PA; Filippatos G; van der Meer P; Ponikowski P; Rasmussen HS; Lavin PT; Singh B; Yang A; Deedwania P
    Eur J Heart Fail; 2015 Oct; 17(10):1050-6. PubMed ID: 26011677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study.
    Roger SD; Lavin PT; Lerma EV; McCullough PA; Butler J; Spinowitz BS; von Haehling S; Kosiborod M; Zhao J; Fishbane S; Packham DK
    Nephrol Dial Transplant; 2021 Jan; 36(1):137-150. PubMed ID: 32030422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium zirconium cyclosilicate increases serum bicarbonate concentrations among patients with hyperkalaemia: exploratory analyses from three randomized, multi-dose, placebo-controlled trials.
    Roger SD; Spinowitz BS; Lerma EV; Fishbane S; Ash SR; Martins JG; Quinn CM; Packham DK
    Nephrol Dial Transplant; 2021 Apr; 36(5):871-883. PubMed ID: 32588050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum potassium response to single-dose sodium zirconium cyclosilicate for the treatment of asymptomatic hyperkalemia in hospitalized patients.
    Lewis H; Stamper B; Yungkurth AC
    Pharmacotherapy; 2024 Jan; 44(1):13-21. PubMed ID: 37475499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DIALIZE China: A Phase IIIb, Randomized, Placebo-Controlled Study to Reduce Predialysis Hyperkalemia With Sodium Zirconium Cyclosilicate in Chinese Patients.
    Ni Z; Lu R; Xu X; Bian X; Zhou Z; Yang J; Luo Q; Chen M; Chen C; Sun X; Yu L; He Q; Jiang H; Yuan W; Li Y; Zhou R; Wang J; Zhang X; Zuo L; Meng X; Chang Z; Zhao J; Wessman P; Xiang P;
    Clin Ther; 2023 Jul; 45(7):633-642. PubMed ID: 37385905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: the randomized, placebo-controlled HARMONIZE-Global study.
    Zannad F; Hsu BG; Maeda Y; Shin SK; Vishneva EM; Rensfeldt M; Eklund S; Zhao J
    ESC Heart Fail; 2020 Feb; 7(1):54-64. PubMed ID: 31944628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacodynamic Dose-Response Analysis of Serum Potassium Following Dosing with Sodium Zirconium Cyclosilicate.
    Penland RC; Åstrand M; Boulton DW; Någård M
    Clin Pharmacokinet; 2024 Apr; 63(4):551-560. PubMed ID: 38504082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic Review and Meta-Analysis of Patiromer and Sodium Zirconium Cyclosilicate: A New Armamentarium for the Treatment of Hyperkalemia.
    Meaney CJ; Beccari MV; Yang Y; Zhao J
    Pharmacotherapy; 2017 Apr; 37(4):401-411. PubMed ID: 28122118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single Dose of Sodium Zirconium Cyclosilicate Versus Sodium Polystyrene Sulfonate in Hospitalized Patients With Hyperkalemia.
    Yoo N; Song YB; Dubinsky I; Altshuler J
    Ann Pharmacother; 2023 Sep; 57(9):1044-1052. PubMed ID: 36637028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of effectiveness and safety of sodium polystyrene sulfonate and sodium zirconium cyclosilicate for treatment of hyperkalemia in hospitalized patients.
    Sullivan E; Ruegger M; Dunne I; Sutaria N; Towers WF
    Am J Health Syst Pharm; 2023 Sep; 80(18):1238-1246. PubMed ID: 37335862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.